SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention amid volatile crude prices tied to U.S.-Iran conflict and Strait of Hormuz supply risks, alongside reports that OPEC+ will hold production quotas steady. Traders are split between expecting supply disruption to support oil and betting that diplomatic progress, inventory relief, or additional supplies will drive prices lower; some also note UCOs leverage can magnify swings.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Arbitrums emergency freeze of roughly $71 million in ETH linked to the KelpDAO exploit is prompting debate: some traders praise the intervention, while others worry it shows the network can restrict users assets and raises centralization and legal concerns. Separately, holders continue to question whether network growth and Robinhood-related activity will translate into value for the ARB token.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and rising-volume breakout have focused attention on Starknets privacy and Bitcoin DeFi push, especially strkBTC and STRK20, alongside its STARK-based post-quantum security narrative. Bullish traders see the technology and product rollout as a reason for renewed interest, while skeptics point to token unlocks, dilution, and the possibility that the move is short-lived.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A weak U.S. jobs report has traders weighing whether softer employment will reduce pressure for further Fed rate hikes, with some seeing support for equities and others focused on persistent Treasury-yield and oil risks tied to Iran and the Strait of Hormuz. DIA discussion also reflects the Dows perceived lag behind tech, alongside interest in beaten-down consumer and value stocks.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs weaker revenue trend and sharp selloff despite improved profitability have fueled debate over its latest earnings and persistent share-price weakness. Bulls point to the companys cash, buybacks and low valuation, while bears cite soft Chinese consumer demand, e-commerce competition and broader weakness in Chinese stocks.

Cash Cat

A sharp rally followed by volatile pullbacks has driven attention, with traders debating whether dips are buying opportunities or signs of a pump-and-dump. Supporters point to Cash Cats Robinhood-chain association and claimed buyback-and-burn activity, while short-squeeze and further-breakout talk remains speculation; no fresh verified catalyst is established.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos better-than-expected Q2 results and five-year AI data-center hosting agreements with Axe Compute are driving attention, reinforcing the companys pivot toward AI infrastructure and expected revenue growth. Traders are largely optimistic about the contract pipeline, while skeptics question execution, funding needs, and potential dilution.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoins sharp rally from the $50s into the $70s and a potential breakout are driving attention, with traders watching resistance around the mid-$70s and higher levels. Bulls see renewed momentum and accumulation, while skeptics warn the move could fade after Litecoin has repeatedly given back gains; some also point to ETF inflows, LitVM, and the coming halving as possible longer-term catalysts.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cashs sharp rally and volatile pullbacks are driving attention; traders have linked the earlier breakout to CME futures access and a Grayscale filing, while debating whether the gains can hold. Bulls point to BCHs relative strength and anticipated CashVM upgrade, while skeptics question its utility and momentum.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Jobys Texas eIPP flights, autonomous cross-country flight demonstrations, and progress toward FAA certification are fueling attention, but the shares steep decline has prompted debate over whether those milestones justify optimism. Bulls point to commercialization potential and Toyotas manufacturing support, while skeptics cite insider selling, dilution risk, and continued cash burn before certification and meaningful passenger operations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PTGX now at $11.5B fdmc. 😉 
 
Executive Summary 
-- Protagonist Therapeutics is a commercial-stage biopharmaceutical platform redefining peptide therapeutics for hematology, inflammatory, and metabolic conditions. 
-- The core value proposition is anchored on two transformative, de-risked validation events in 2026: the U.S. FDA approval and ongoing commercial launch of ICOTYDE (icotrokinra) by partner J&amp;J, and the NDA Priority Review for rusfertide with an imminent August 2026 PDUFA target action date. 
-- The underlying technology platform specializes in turning complex biological pathways into stable, orally available or highly targeted synthetic peptide drugs, capturing big-molecule efficacy with small-molecule convenience. 
-- Following a massive technical run-up into the $137–$140 range, the company&#39;s valuation heavily prices in flawless execution of its high-tier milestone and royalty capture potential, limiting near-term upside surprises. 
-- Crucially, Protagonist has achieved a permanent operational structural shift by capturing massive, non-dilutive milestone payments and executing a high-conviction collaboration opt-out with Takeda, transforming its risk profile into a highly capitalized ($849.5M cash balance), multi-blockbuster royalty stream vehicle. 
 
Financials (Actuals &amp; Metrics at $150/share) 
-- Fully Diluted Share Count: ~76.22 million shares. (Calculated from 64,672,032 common shares outstanding as of June 30, 2026, plus approximately 6.7 million outstanding options, 1.2 million unvested RSUs, 3.0 million shares remaining reserved under equity plans, and the 650,000 newly approved shares via the 2026 Equity Incentive Plan). 
-- Fully Diluted Market Cap: ~$11.43 billion (at $150/share). 
-- Total Balance Sheet Debt: $0.0 million. (Clean capital structure with zero debt or credit facility draws). 
-- Net Cash &amp; Liquid Position (As of June 30, 2026): $849.5 million. (Consisting of $420.1M in cash and cash equivalents plus $429.4M in current and noncurrent marketable securities, fully reflecting the receipt of the initial $200.0M Takeda opt-out fee). 
-- Monthly Burn and Cash Runway: N/A / Indefinite. R&amp;D operating expenses totaled $42.1 million for Q2 2026. With $849.5 million in cash and an additional $275.0 million in near-term cash milestone receivables due upon the August 2026 rusfertide FDA approval, the company holds multi-year liquidity extending past 2030, offering total capital autonomy to fund internal pipeline development dilution-free. 
 
Pipeline and Stage of Development 
-- ICOTYDE (icotrokinra / JNJ-2113): Approved/Commercial for Moderate-to-Severe Plaque Psoriasis. Mechanism of Action (ICOTYDE): A first-in-class, highly potent oral IL-23 receptor antagonist peptide that selectively blocks IL-23-mediated signaling directly in the gut mucosa, achieving systemic skin clearance without systemic biologic injections. Phase 3 trials ongoing in PsA and UC; Phase 2b/3 in Crohn&#39;s disease. 
-- Rusfertide (PTG-300): NDA under Priority Review for Polycythemia Vera (PV). Mechanism of Action (Rusfertide): An injectable synthetic hepcidin mimetic that restricts iron availability for erythropoiesis, controlling hematocrit levels and reducing the critical thrombotic risks associated with iron-overloaded red blood cell overproduction. 
-- PN-881: Oral IL-17 antagonist peptide. Phase 1 Complete and Advancing Directly to Phase 2b in Plaque Psoriasis in Early Q1 2027.  Mechanism of Action (PN-881): High-potency oral peptide that achieves triple-dimer blockade (IL-17AA, IL-17AF, and IL-17FF), matching the broad-spectrum efficacy profile of bimekizumab in an oral format. 
-- PN-477: Subcutaneous and Oral triple GLP-1/GIP/Glucagon receptor agonist peptide; Pre-clinical / IND-enabling (Phase 1 subcutaneous to initiate mid-2026; oral in Q1 2027). Mechanism of Action (PN-477): Multi-receptor metabolic peptide designed to optimize metabolic homeostasis, weight loss, and glycemic regulation. 
-- PN-458: Oral (PN-458o) and Subcutaneous (PN-458sc) dual GLP-1/GIP receptor agonist peptide; Pre-clinical / IND-enabling (IND-enabling studies ongoing; Phase 1 trial initiation anticipated in H2 2027). Mechanism of Action (PN-458): Targeted dual incretin receptor agonist engineered to enhance insulin secretion, improve glycemic control, and suppress appetite for obesity and metabolic indications. 
 
Catalyst Readout Timeline 
-- August 2026: FDA PDUFA target action date for rusfertide in Polycythemia Vera (triggers $275M cash payout). 
-- Q3 2026: First quarterly ICOTYDE commercial net sales royalty report from partner J&amp;J. 
-- H2 2026: European EMA regulatory decision and international commercial launch rollouts for ICOTYDE by J&amp;J. 
-- Early Q1 2027: Phase 2b trial initiation for oral IL-17 inhibitor PN-881 in moderate-to-severe plaque psoriasis. 
-- H1 2027: Top-line Phase 1 data readout for subcutaneous triple metabolic agonist PN-477. 
 
Competition and Competitive Positioning 
-- The First-Generation Oral Status Quo: BMS’s Sotyktu (deucravacitinib) and Amgen’s Otezla (apremilast). ICOTYDE holds a clear structural advantage, delivering superior skin clearance (up to 55% PASI 90 at week 16) compared to Sotyktu&#39;s modest 32%–42% PASI 90, effectively raising the baseline performance expectation for oral psoriasis agents. 
-- Next-Generation Oral TYK2 Threat Profile: Takeda’s zasocitinib (TAK-279) and Alumis’s envudeucitinib (ESK-001) present intense, newly validated oral competition following stellar late-breaking Phase 3 data at the March 2026 AAD meeting. 
-- Head-to-Head Oral Efficacy Pressures: Takeda’s once-daily zasocitinib reported an impressive ~61% to 71% sPGA 0/1 and up to 61% PASI 90 at week 16, while Alumis’s envudeucitinib demonstrated a ~65% PASI 90 and over 40% PASI 100 at week 24. These deep clinical responses outperform ICOTYDE&#39;s peak 55% PASI 90, threatening its positioning as the undisputed premier high-efficacy oral option. 
-- Long-Acting Biologic Displacement Risk: Established blockbusters like AbbVie&#39;s Skyrizi (anti-IL-23) and upcoming ultra-long-acting biologics like Oruka Therapeutics’ pipeline agents present severe convenience hurdles. While ICOTYDE eliminates the needle, it requires a strict daily oral routine, whereas modern biologics offer 100% adherence guarantees via infrequent quarterly or bi-annual injections. 
-- J&amp;J Commercial Defense &amp; In-Class MoA Edge: To counter both next-gen TYK2s and long-acting injections, J&amp;J will aggressively position ICOTYDE as a highly unique gut-restricted mechanism that blocks IL-23 directly at the source. This completely avoids the off-target lab abnormalities and class-wide acne/headache side effects seen with systemic allosteric TYK2 inhibition. 
-- Hematology Landscape Resiliency: In Polycythemia Vera, rusfertide maintains a highly insulated competitive moat over therapeutic phlebotomy and Jakafi (ruxolitinib). It is uniquely positioned as a symptom-resolving, non-cytoreductive choice that protects the bone marrow while eliminating chronic iron deficiency. 
 
M&amp;A Strategy &amp; Buyout Valuation Matrix 
-- Strategic Fit (Novo Nordisk / J&amp;J Arbitrage): Protagonist offers an acquirer immediate access to a double-blockbuster cash flow vector. A clean cash acquisition by Novo Nordisk allows Novo to capture Protagonist&#39;s Vectrix™ macrocyclic oral peptide platform, achieve a low-risk entry into I&amp;I/hematology royalties, and onboard the PN-477 metabolic triple agonist. 
-- The Multi-Party Cash Split Mechanics: J&amp;J executes a structured option to buy out the ICOTYDE royalty stream (6%–10%) and reclaim $425M in remaining milestones for a $6.5B cash fee paid directly to Novo. 
-- Updated Strategic Buyout Valuation Matrix: 
Aggressive Control Premium Baseline: Implied strategic transaction value of $185.00 to $205.00 per share ($14.1B to $15.6B fully diluted strategic valuation). 
Total Fronted Cash (Novo Nordisk):$14.8 Billion upfront. 
J&amp;J ICOTYDE Royalty/Milestone Buyout Influx:+$6.5 Billion paid directly from J&amp;J to Novo Nordisk. 
Takeda Rusfertide Value Retention (Novo Net Hold):+$2.5 Billion net present value attached to the 14%–29% global hematology royalty engine. 
Protagonist Balance Sheet Net Cash Recovery:+$1.12 Billion in cash ($849.5M cash balance + $275M pending approval milestone). 
Effective Net Purchase Price for Platform &amp; Metabolic Pipeline:~$4.68 Billion. 
 
Bull Thesis 
-- Explosive Blockbuster Royalty Capture: Partner J&amp;J projects ICOTYDE peak sales exceeding $10 billion. Protagonist is positioned to harvest significant tiered upward double-digit royalties (6%–10%) alongside $580M in remaining milestones. 
-- High-Conviction Rusfertide Value Capture: The Takeda opt-out unlocked $200M received in Q2, a pending $200M approval fee + $75M approval milestone, and elevated global royalties of 14%–29% on net worldwide sales, while shifting all U.S. launch costs onto Takeda. 
-- Invaluable Cash Cushion &amp; Capital Autonomy: Possessing $849.5 million in cash with zero debt completely isolates Protagonist from volatile capital markets, making dilutive equity raises irrelevant. 
-- Validated Peptide Discovery Platform: Skipping Phase 2a and advancing PN-881 directly to Phase 2b de-risks the wholly owned internal pipeline, proving the platform&#39;s modular discovery efficiency. 
 
Bear Thesis 
-- Valuation &amp; Insider Trimming: Trading at a ~$10.5 Billion fully diluted market cap leaves little room for clinical or commercial missteps. A wave of Form 4 filings shows pre-planned 10b5-1 trimming across executives (CEO, CFO, CMO) throughout May and June 2026, signaling valuation maturity. 
-- Extreme Reliance on Partner Execution: Protagonist is fully dependent on commercial execution by J&amp;J and Takeda. Any launch delays or pricing pushback directly bottlenecks near-term royalty streams. 
-- Downstream Payer and Access Hurdles: Oral therapeutics entering crowded fields like psoriasis face aggressive step-edit protocols from PBMs favoring low-cost generics before allowing access to branded agents.